The Career of Ingemar Pongratz
Ingemar Pongratz studied at Stockholm University. There he studied Toxicology, Biochemistry, and Organic Chemistry. After working years of study Ingemar Pongratz successfully defended his Ph D thesis in December 1996 and began a new position at the Department for Cell and Molecular Biology. There he authored several peer reviewed articles that appeared in scientific journals and also supervised other PhD students.
In 2002 Ingemar Pongratz decided to leave the Department for Cell and Molecular Biology and move to the Department for Biosciences and Nutrition and work again with Professor Jan-Åke Gustafsson.
This move meant several changes for Ingemar Pongratz. Ingemar had now the opportunity to establish himself as a fully independent scientist, with several additional Ph D students and post-docs, whch all successfully prepared several scientific articles during their stay in Ingemar Pongratz group.
In addition, Ingemar started to work closely with the difficult and challenging process of EU funding applications.
In this area Ingemar Pongratz successfully attracted EU funding while at the same time remained an active and successful researcher with over 40 published articles and reviews in scientific journals. The research activities of Ingemar Pongratz were centered at the crosstalk between hormonal signaling primarily estrogen signaling and the interference of these pathways by environmental pollutants. In addition, Ingemar Pongratz co-authored articles about a novel immune system regulator and how compounds derived from amino acids and other dietary sources regulate this protein and modulate the immune system.
In 2011-2012, Ingemar left the Karolinska Institute and established himself as a consultant and entrepreneur.
His consultancy, Pongratz Consulting, actively supports client to apply for EU funding and has in little more than 24 months already helped customers to obtain over 20 Million EUR worth of projects.
In addition, Ingemar Pongratz has also established Fenix Scientific, a research intensive company which aims to commercially exploit some of the research finding. The company is currently preparing itself to approach and engage with different investors both in Europe and in the US.